Skip to content

Study · Case report or series · n = 3 · 2026

3 results

Safety and effectiveness of setmelanotide in young patients with severe obesity due to craniopharyngioma: a real world monocentric experience.

Cotta OR, Morgante C, Giandalia A, Angileri F, Ferrau' F, Cannavo' S

Journal of endocrinological investigation22 Jun 2026

PMID42329358 (opens in a new tab)DOI10.1007/s40618-026-02950-z (opens in a new tab)PepBankPUB-42329358
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In young adults with post-craniopharyngioma hypothalamic obesity receiving setmelanotide, adverse effects were mild and non-limiting.

    In plain wordsIn young adults receiving setmelanotide, adverse effects were mild and did not limit treatment.

    Peptide
    Setmelanotide
    Outcome
    Not applicableAdverse effect severity
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse effects were mild and non-limiting.
    2 context sentences
    Summary · context
    We performed a retrospective review of patients with post-CP HO treated with setmelanotide at our center, collecting clinical, metabolic, and treatment-related data.
    Summary · context
    Three young adults with HO after surgery for CP were included.
  2. 02HumanCase report or seriesEfficacy outcome

    Two young adults with post-craniopharyngioma hypothalamic obesity had lower weight, BMI, waist circumference, triglycerides and insulin during setmelanotide treatment.

    In plain wordsTwo young adults receiving setmelanotide had lower weight, BMI, waist size, triglycerides and insulin over 6-9 months.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight, BMI, waist circumference, triglycerides and insulin
    Study

    n = 2

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 6-9 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment responses were variable: one patient discontinued setmelanotide after continued weight gain, while two experienced reductions in weight, BMI, waist circumference, triglycerides and insulin levels over 6-9 months.
    2 context sentences
    Summary · context
    We performed a retrospective review of patients with post-CP HO treated with setmelanotide at our center, collecting clinical, metabolic, and treatment-related data.
    Summary · context
    Three young adults with HO after surgery for CP were included.
  3. 03HumanCase report or seriesEfficacy outcome

    One young adult with post-craniopharyngioma hypothalamic obesity continued gaining weight during setmelanotide treatment.

    In plain wordsOne young adult with hypothalamic obesity continued gaining weight during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    IncreaseContinued weight gain
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment responses were variable: one patient discontinued setmelanotide after continued weight gain, while two experienced reductions in weight, BMI, waist circumference, triglycerides and insulin levels over 6-9 months.
    2 context sentences
    Summary · context
    We performed a retrospective review of patients with post-CP HO treated with setmelanotide at our center, collecting clinical, metabolic, and treatment-related data.
    Summary · context
    Three young adults with HO after surgery for CP were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.